August marks the end of OncoLog’s 62 years of publication. The current issue will be the final one.
The University of Texas MD Anderson Cancer Center has published OncoLog continuously since 1956, when it was called simply Newsletter. The name was changed to OncoLog in 1983. OncoLog became available online in 2003.
Although the name and look of the newsletter have changed over the years, its mission has remained the same: to inform community physicians about the latest advances in cancer care and research. Over the decades, OncoLog has chronicled milestones such as using vincristine as the first successful chemotherapy in children with Wilms tumors (1960), developing limb-sparing surgery for cancers of the extremities (1966), proving that lumpectomy is as effective as radical mastectomy for some patients with breast cancer (1976), establishing the benefit of neoadjuvant chemotherapy for breast cancer (1988), demonstrating the efficacy of intensity-modulated radiation therapy against various cancers (2007), showing the benefit of personalized targeted therapy for lung cancer (2010), and developing chimeric antigen receptor T cells to treat B cell malignancies (2014).
Although OncoLog will no longer be published, physicians will continue to have access to MD Anderson’s research news via the Cancer Frontline blog. In addition, numerous MD Anderson resources for community physicians—including clinical tools such as cancer screening and treatment algorithms—are available at www.mdanderson.org/for-physicians.html.
MD Anderson’s commitment to having open lines of communication with community physicians remains a priority. “As we look into the future, we’re going to be enhancing our strategic partnerships with community physicians, and that will be an important part of how we manage many aspects of our patients’ care,” said Peter W.T. Pisters, M.D., president of MD Anderson.
OncoLog, August 2018, Volume 63, Issue 8